Economic evidence for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

#4576

Introduction: Treatment failure and disease progression (PD) in neuroendocrine tumours (NETs), a rare group of malignancies, are common due to limited targeted treatments.

Aim(s): To identify economic data (cost-effectiveness [CE], health-related quality of life [HRQoL] and cost and resource use [CRU]) for patients with pancreatic (pNETs) or extra-pancreatic (epNETs) NETs who have experienced treatment failure or PD following prior treatments.

Materials and methods: In May 2024, databases and grey literature sources were searched. Eligible studies reported economic data for adults with NETs who experienced treatment failure or PD following: everolimus, sunitinib, 177Lu-dotatate, CAPTEM, STZ/5-FU, FOLFOX or IFN-∝.

Conference:

Presenting Author:

Authors: Karim E, Sola-Morales O, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine Tumour, Systematic Literature Review, Economic,